$49.1 BillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
$223.25 - $468.55The lowest and highst price in the last 52 weeks.
25.58xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$0.00 (0.0%)Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
|Market Cap||$49.1 Billion|
|Enterprise Value||$53.8 Billion|
|Dividend Yield||$0.00 (0.0%)|
|1 Year Return||+18.7%|
|Outstanding Shares||149 Million|
|Avg 30 Day Volume||1.34 Million|
|Earnings per Share||$12.50|
|Price to Sales Ratio||3.89|
|Price to Book Ratio||4.6|
|Revenue to Enterprise Value||4.27|
|EBIT to Enterprise Value||15.38|
|Total Debt to Enterprise Value||0.14|
|Debt to Equity||0.68|
|Gross Profit||$10.8 Billion|
|Net Income||$3.01 Billion|
|Quarterly Earnings Growth (YoY)||-70.7%|
|Return on Equity||28.19%|
|Return on Assets||12.63%|
|Return on Invested Capital||16.91%|
At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.
Related Stocks: MLCO , MCK , BABA , PKX , SKM , CMCSA , IIVI , BUR , LLY , RDY , MOS , BAC , BIIB , JD ,GuruFocus, about 16 hours ago
Theres a new drug on the block to treat Alzheimers disease. On June 7, the United States Food and Drug Administration approved aducanumab (brand name Aduhelm), made by Biogen, the first new drug fo...Philippine Canadian Inquirer, 2 days ago
Adalimumab market report presents the best market and business solutions to Pharmaceutical industry in this rapidly revolutionizing market place to thrive in the market. Market definition gives the...OpenPR, 3 days ago